Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER FINANCIAL RESULTS
Date:11/12/2013

of 2014.  Based on these factors, we are modifying our revenue, expense and loss guidance for 2013.  However, importantly, we are maintaining our cash balance guidance as we continue to expect Senomyx will end the year with more than $30 million in cash," Rogers noted.

For the full year 2013, Senomyx now expects:

  • Total revenues of $29 million to $30 million, of which approximately $5 million is commercial revenues
  • Total operating expenses of approximately $41 million, of which an estimated $4 million is non-cash, stock-based compensation expense
  • Net loss of $11 million to $12 million
  • Basic and diluted net loss of $0.27 to $0.29 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Financial Outlook: "When modeling our financial forecast, we compartmentalize our commercial revenue opportunities into three broad categories:  Senomyx's royalty-based collaborations with Firmenich, Nestle, and Ajinomoto; our direct sales initiative; and our PepsiCo collaboration.  Commercial revenues are modeled based on projections from our collaborators for royalty-based collaborations, plus current best estimates for sales potential from our nascent direct sales initiative.  From these three categories of commercial revenue opportunities, we expect approximately $10 million in commercial revenues in 2014, and approximately $25 million in commercial revenues in 2015.  A key assumption in our projections is that S617 will receive regulatory approval and will be commercialized in 2014.  We anticipate this growth in commercial revenues will be primarily driven by our collaboration with PepsiCo and Senomyx's direct sales.  In addition, we expect that the successful implementation of our direct sales initiative will begin to yield compelling results over the next two years and products from our Sweet Taste Program
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
    3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
    4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
    5. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
    6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
    7. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
    8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
    9. Senomyx Announces Management Update
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... ... July 27, 2015 , ... This is ... report provides a basic overview of the industry including definitions, classifications, applications and ... including development trends, competitive landscape analysis, and key regions development status. Development policies ...
    (Date:7/27/2015)... --  Inocucor Technologies Inc ., the agriculture biotech ... has received a notice of allowance from the ... application to protect Inocucor consortia and unique microbial ... on farms and in greenhouses. This ... consortium and its fermentation byproducts, which are the ...
    (Date:7/27/2015)... , July 27, 2015 According to ... Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, ... Europe , Asia-Pacific , ... The global biopreservation media market was valued at $247.7 million ... million by 2019, at a CAGR of 18.2% between 2014 ...
    (Date:7/27/2015)... WESTBROOK, Maine , July 27, 2015 ... that more than 8,000 clinics have submitted over 100,000 ... SDMA, testing in just the first 10 days since ... Chronic kidney disease (CKD) is a leading cause of ... from the submitted specimens are consistent with generally accepted ...
    Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
    ... RIVER, N.Y., June 20, 2011 ... provider of software and services for health and ... 4.2 electronic health record (EHR) software for behavioral ... ARRA Ambulatory Certification. (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO) ...
    ... VICTORIA, Australia, June 20, 2011 Genetic Technologies Limited ... North American division, Phenogen Sciences Inc., has launched the ... risk.   Phenogen Sciences will target its ... US metro-markets.  The company has deployed its sales force ...
    ... ,Graphene, a one-atom-thick layer of graphitic carbon, has the ... But its unique properties, and the shrinking scale of ... produce on a large scale. In ... had overcome some of these difficulties and were able ...
    Cached Biology Technology:CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 2CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 3CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 4Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
    (Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
    (Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
    (Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
    Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
    ... a new study, Dartmouth researchers describe the structure of a ... Vibrio cholerae , the bacteria that causes cholera. Buried within ... that appears to inhibit ToxT, which prevents the bacteria from ... threatening, and, according to the World Health Organization, cholera remains ...
    ... In fact, toe running is far more efficient than landing ... distance endurance running, humans are some of the best-adapted animals ... why have we stuck with our inefficient heel first footfall ... marathon running? This paradox puzzled Nadja Schilling and Christoph Anders ...
    ... Scientists have pinpointed specific mutations that allow a common ... in the March issue of the Journal of General ... viruses and hosts could provide insight to how some viruses ... a better idea of how animal diseases are generated. ...
    Cached Biology News:Dartmouth researchers describe how the cholera bacteria becomes infectious 2Human use heel first gait because it is efficient for walking 2The genetic secrets to jumping the species barrier 2
    The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
    Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
    ... antibody raised against a partial ... Immunogen: SLC22A3 (NP_068812, 90 ... recombinant protein with GST tag. ... NM_021977 ...
    Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
    Biology Products: